Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Earnings on Monday

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Monday, February 10th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $19.05 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Trading Down 5.2 %

Shares of NASDAQ ARWR traded down $1.03 during trading on Tuesday, reaching $18.89. The stock had a trading volume of 1,772,893 shares, compared to its average volume of 2,371,200. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $36.72. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The business's 50-day moving average price is $20.23 and its 200-day moving average price is $21.25. The company has a market cap of $2.36 billion, a P/E ratio of -3.76 and a beta of 0.95.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares of the company's stock, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the business's stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the sale, the director now directly owns 36,740 shares of the company's stock, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,432 shares of company stock valued at $2,957,986. 4.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ARWR has been the subject of several analyst reports. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Sanford C. Bernstein lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research note on Friday, November 29th. StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday, December 20th. Piper Sandler lowered their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.